Companies › Strand Therapeutics
2 active drug programs in 2 registered trials: 2 Phase 1; Oncology; next expected readout May 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| STX-001 Self-replicating RNA encoding IL-12 delivered via lipid nanoparticle (LNP) for intratumora | IL12 | Phase 1 | Advanced Solid Tumor | May 2027 |
| STX-003 LNP-formulated self-replicating mRNA encoding human IL-12 with miRNA target sites for cont | IL12 | Phase 1 | Advanced Solid Tumor | Jul 2030 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06249048 | STX-001 | Phase 1 | Advanced Solid Tumor | Oncology | May 2027 |
| NCT07751042 | STX-003 | Phase 1 | Advanced Solid Tumor | Oncology | Jul 2030 |
Geneos Therapeutics Suzhou Abogen Biosciences Imunon VLP Therapeutics Sonnet BioTherapeutics Kangabio AUSTRALIA enGene Inovio Pharmaceuticals Trogenix
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.